NCODA Positive Quality Interventions

Written By: Michelle Phillips, PharmD, BCOP
Institution: Wilmot Cancer Center

Darolutamide (Nubeqa®) In the Treatment of Non-Metastatic Castration Resistant Prostate Cancer

Description: The purpose of this PQI is to summarize the process for initiating and monitoring darolutamide therapy in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).

Background:
Darolutamide is an androgen receptor inhibitor indicated for the treatment of adult patients with[1]:

- nmCRPC in combination with ADT
- mCSPC in combination with docetaxel and androgen deprivation therapy (ADT)
- mCSPC in combination with ADT

Most common adverse reactions (>10% with a ≥2% increase over placebo) including laboratory test abnormalities[1]: increased AST, decreased neutrophil count, increased bilirubin, fatigue, and increased ALT

PQI Process:

- Verify diagnosis of nmCRPC
- Ensure appropriate dose: darolutamide 600 mg (two 300 mg tablets) twice daily[1]
  - For patients with severe renal impairment (eGFR 15-29 mL/min) the recommended dose is 300 mg BID
  - For patients with moderate hepatic impairment (Child-Pugh class B) recommended dose is 300 mg BID
- Ensure patient is on androgen deprivation therapy; GnRH agonist or antagonist
- Obtain labs: complete blood count with differential and comprehensive metabolic panel, PSA, and testosterone at baseline, monthly, and as clinically indicated
- Check for clinically relevant drug interactions
  - Darolutamide concentrations may decrease with PGP and moderate/strong CYP3A4 inducers; avoid concomitant use
  - Darolutamide concentrations may increase with PGP and strong CYP3A4 inhibitors; monitor for increase adverse effects
- Darolutamide may increase concentrations of breast cancer resistance protein substrates
- Dose modifications for toxicities—for Grade ≥ 3 toxicity or other intolerable adverse events, withhold or reduce to 300 mg twice daily until symptom resolution
  - May resume 600 mg twice daily upon resolution
  - Doses < 300 mg twice daily not recommended

Patient-Centered Activities:

- Provide patient with darolutamide Patient Education Sheet
- Ensure patient receiving concomitant gonadotropin releasing hormone antagonist
- Take twice daily
- Swallow tablets whole and take with food
- Missed dose: Take as soon as a dose is remembered prior to the next scheduled dose; do not take two doses together to make up for a missed dose

- Review potential side effects including fatigue, decreased neutrophil count, pain in extremities, and rash
- Males with female partners of reproductive potential should use highly effective contraception during treatment and for one week after last dose due to risk of embryo-fetal toxicity
- Patient Assistance: NCODA Financial Assistance Tool

References:

1. Nubeqa® (darolutamide) [prescribing information].
2. Bastos DA, et al. Darolutamide for castration-resistant prostate cancer. *Onco Targets Ther.* 2019; 12: 8769 – 8777.
2. National Comprehensive Cancer Network. Prostate cancer.
3. Fizazi K, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. *New Eng J Med*. 2019; 380: 1235 – 1246.